Genprex, Inc. (NASDAQ:GNPX) Short Interest Up 46.5% in December

by · The Markets Daily

Genprex, Inc. (NASDAQ:GNPX – Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 634,600 shares, a growth of 46.5% from the November 30th total of 433,100 shares. Approximately 7.7% of the company’s shares are sold short. Based on an average daily volume of 9,290,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Genprex

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC increased its holdings in Genprex, Inc. (NASDAQ:GNPX – Free Report) by 122.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 218,000 shares of the company’s stock after acquiring an additional 120,132 shares during the period. Armistice Capital LLC owned approximately 10.39% of Genprex worth $411,000 at the end of the most recent quarter. Institutional investors own 14.05% of the company’s stock.

Genprex Price Performance

Genprex stock traded down $0.01 during midday trading on Monday, hitting $0.87. 191,295 shares of the stock were exchanged, compared to its average volume of 2,561,130. The stock’s 50-day simple moving average is $1.43 and its 200 day simple moving average is $1.24. Genprex has a fifty-two week low of $0.28 and a fifty-two week high of $14.40.

About Genprex

(Get Free Report)

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.

Recommended Stories